Previous 10 | Next 10 |
2024-05-04 03:39:35 ET Summary Schwab U.S. Dividend Equity ETF is a popular choice for income-oriented investors, diversification and a defensive approach. SCHD offers exposure to dividend-paying firms with healthy balance sheets, offering investors resilience in turbulent times. ...
2024-05-03 18:15:34 ET Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The stock rose by almost 12% on Friday, but much of that was due ...
2024-05-03 13:45:00 ET Summary Amgen released its Q1'24 earnings earlier today with revenues increasing 22% YoY to $7.45bn, with non-GAAP net income of $2.14bn. Non-GAAP EPS fell by 1% YoY to $3.96 per share, and GAAP EPS to $(0.21) owing to underlying Beigene holding and costs re...
2024-05-03 12:29:38 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Amgen stock rallies 13% on GLP-1 weight-loss drug update ...
Stocks jumped sharply Friday after a softer-than-expected April jobs report boosted hopes that the Federal Reserve could start cutting interest rates soon. The Dow Jones Industrials popped 524,51 points, or 1.4%, to begin Friday at 38,750.17. The S&P 500 galloped 62.12 points, or 1.2%...
Amgen Inc. (NASDAQ: AMGN) is one of today's top gainers. The company's shares have moved 12.15% on the day to $312.21. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, ...
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-03 06:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for AMGN on May 3, 2024 04:38AM ET. The previous analyst recommendation was Underweight. AMGN was trading at $278.39 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-03 05:14:40 ET More on related stocks: Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Apple Inc. (AAPL) Q2 2024 Earnings Call Transcript Cloudflare, Inc. (NET) Q1 2024 Earnings Call Transcript Apple in charts: iPhone revenue slumps Y/Y; services ...
2024-05-02 21:12:05 ET Amgen, Inc. (AMGN) Q1 2024 Earnings Conference Call May 02, 2024, 16:30 ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Research and Development & Chief Scientific Offic...
News, Short Squeeze, Breakout and More Instantly...
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial o...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD PR Newswire Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels ...
2024-05-19 06:15:00 ET Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same mol...